{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T22:51:46Z","timestamp":1772059906777,"version":"3.50.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,4,20]],"date-time":"2024-04-20T00:00:00Z","timestamp":1713571200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,4,20]],"date-time":"2024-04-20T00:00:00Z","timestamp":1713571200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["72174142"],"award-info":[{"award-number":["72174142"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Haisco Pharmaceutical Group"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Patient"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1007\/s40271-024-00694-7","type":"journal-article","created":{"date-parts":[[2024,4,21]],"date-time":"2024-04-21T02:38:00Z","timestamp":1713667080000},"page":"565-574","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Evaluating the Preferences and Willingness-to-Pay for Oral Antidiabetic Drugs Among Patients with Type 2 Diabetes Mellitus in China: A Discrete Choice Experiment"],"prefix":"10.1007","volume":"17","author":[{"given":"Ling-Hsiang","family":"Chuang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huanlan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tianqi","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5454-3383","authenticated-orcid":false,"given":"Shitong","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,4,20]]},"reference":[{"key":"694_CR1","volume":"369","author":"Y Li","year":"2020","unstructured":"Li Y, Teng D, Shi X, Qin G, Qin Y, Quan H, et al. Prevalence of diabetes recorded in mainland China using 2018 diagnostic criteria from the American Diabetes Association: national cross sectional study. Br Med J (Clinical research ed). 2020;369: m997.","journal-title":"Br Med J (Clinical research ed)."},{"key":"694_CR2","unstructured":"A mass survey of diabetes mellitus in a population of 300,000 in 14 provinces and municipalities in China (author's transl). Zhonghua nei ke za zhi. 1981;20(11):678\u201383."},{"key":"694_CR3","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.2147\/DMSO.S202193","volume":"12","author":"X Tang","year":"2019","unstructured":"Tang X, Yan X, Zhou H, Yang X, Niu X, Liu J, et al. Prevalence and identification of type 1 diabetes in Chinese adults with newly diagnosed diabetes. Diabetes Metab Syndr Obes. 2019;12:1527\u201341.","journal-title":"Diabetes Metab Syndr Obes."},{"issue":"4","key":"694_CR4","first-page":"315","volume":"13","author":"Chinese Diabetes Society","year":"2021","unstructured":"Chinese Diabetes Society. Guideline for the prevention and treatment of type 2 diabetes mellitus in China (2020 edition). Chin J Diabetes. 2021;13(4):315\u2013409.","journal-title":"Chin J Diabetes"},{"issue":"10","key":"694_CR5","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1007\/s00125-004-1527-z","volume":"47","author":"PM Clarke","year":"2004","unstructured":"Clarke PM, Gray AM, Briggs A, Farmer AJ, Fenn P, Stevens RJ, et al. A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68). Diabetologia. 2004;47(10):1747\u201359.","journal-title":"Diabetologia"},{"issue":"2","key":"694_CR6","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1002\/ddr.21579","volume":"81","author":"K Jash","year":"2020","unstructured":"Jash K, Gondaliya P, Kirave P, Kulkarni B, Sunkaria A, Kalia K. Cognitive dysfunction: a growing link between diabetes and Alzheimer\u2019s disease. Drug Dev Res. 2020;81(2):144\u201364.","journal-title":"Drug Dev Res"},{"issue":"6","key":"694_CR7","doi-asserted-by":"publisher","first-page":"733","DOI":"10.4093\/dmj.2019.0177","volume":"43","author":"S Suh","year":"2019","unstructured":"Suh S, Kim KW. Diabetes and cancer: cancer should be screened in routine diabetes assessment. Diabetes Metab J. 2019;43(6):733\u201343.","journal-title":"Diabetes Metab J"},{"key":"694_CR8","doi-asserted-by":"publisher","first-page":"994766","DOI":"10.3389\/fpubh.2022.994766","volume":"10","author":"K Asmat","year":"2022","unstructured":"Asmat K, Dhamani K, Gul R, Froelicher ES. The effectiveness of patient-centered care vs. usual care in type 2 diabetes self-management a systematic review and meta-analysis. Front Public Health. 2022;10:994766.","journal-title":"Front Public Health"},{"issue":"5","key":"694_CR9","first-page":"52","volume":"15","author":"S Liu","year":"2022","unstructured":"Liu S, Yang Y, Sun H, Ming J, Chen Y. The significance, approaches and challenges of integrating patient preference evidence into health technology assessment. Chin J Health Policy. 2022;15(5):52\u20138.","journal-title":"Chin J Health Policy"},{"issue":"10","key":"694_CR10","first-page":"713","volume":"58","author":"Chinese Diabetes Society, National Office for Primary Diabetes Care","year":"2019","unstructured":"Chinese Diabetes Society, National Office for Primary Diabetes Care. National handbook for the prevention and control of diabetes in primary care. Zhonghua Nei Ke Za Zhi. 2019;58(10):713\u201335.","journal-title":"Zhonghua Nei Ke Za Zhi"},{"issue":"4","key":"694_CR11","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.jval.2010.11.013","volume":"14","author":"JF Bridges","year":"2011","unstructured":"Bridges JF, Hauber AB, Marshall D, Lloyd A, Prosser LA, Regier DA, et al. Conjoint analysis applications in health\u2014a checklist: a report of the ISPOR Good Research Practices for Conjoint Analysis Task Force. Value Health. 2011;14(4):403\u201313.","journal-title":"Value Health"},{"issue":"3","key":"694_CR12","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s40271-014-0057-0","volume":"7","author":"LB von Arx","year":"2014","unstructured":"von Arx LB, Kjeer T. The patient perspective of diabetes care: a systematic review of stated preference research. Patient. 2014;7(3):283\u2013300.","journal-title":"Patient"},{"issue":"1","key":"694_CR13","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1186\/s12913-018-3484-0","volume":"18","author":"S Fifer","year":"2018","unstructured":"Fifer S, Rose J, Hamrosi KK, Swain D. Valuing injection frequency and other attributes of type 2 diabetes treatments in Australia: a discrete choice experiment. BMC Health Serv Res. 2018;18(1):675.","journal-title":"BMC Health Serv Res"},{"issue":"4","key":"694_CR14","doi-asserted-by":"publisher","first-page":"e010942","DOI":"10.1136\/bmjgh-2022-010942","volume":"8","author":"S Liu","year":"2023","unstructured":"Liu S, Liu J, Si L, Ke X, Liu L, Ren Y, et al. Patient preferences for anti-hyperglycaemic medication for type 2 diabetes mellitus in China: findings from a national survey. BMJ Glob Health. 2023;8(4):e010942.","journal-title":"BMJ Glob Health"},{"key":"694_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2021.782964","volume":"9","author":"Y Huang","year":"2021","unstructured":"Huang Y, Huang Q, Xu A, Lu M, Xi X. Patient preferences for diabetes treatment among people with type 2 diabetes mellitus in China: a discrete choice experiment. Front Public Health. 2021;9: 782964.","journal-title":"Front Public Health"},{"key":"694_CR16","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.2147\/PPA.S367985","volume":"16","author":"Y Lv","year":"2022","unstructured":"Lv Y, Ren R, Tang C, Song K, Li S, Wang H. Preferences for patients with type 2 diabetes mellitus for medications in Shandong Province, China: a discrete choice experiment. Patient Prefer Adherence. 2022;16:2335\u201344.","journal-title":"Patient Prefer Adherence"},{"key":"694_CR17","doi-asserted-by":"publisher","DOI":"10.1007\/s40271-024-00673-y","author":"AC M\u00fchlbacher","year":"2024","unstructured":"M\u00fchlbacher AC, de Bekker-Grob EW, Rivero-Arias O, Levitan B, Vass C. How to present a decision object in health preference research: attributes and levels, the decision model, and the descriptive framework. Patient. 2024. https:\/\/doi.org\/10.1007\/s40271-024-00673-y. (Online ahead of print).","journal-title":"Patient"},{"key":"694_CR18","doi-asserted-by":"publisher","DOI":"10.1007\/s40271-023-00671-6","author":"DA Marshall","year":"2024","unstructured":"Marshall DA, Veldwijk J, Janssen EM, Reed SD. Stated-preference survey design and testing in health applications. Patient. 2024. https:\/\/doi.org\/10.1007\/s40271-023-00671-6. (Online ahead of print).","journal-title":"Patient"},{"issue":"7","key":"694_CR19","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.2337\/dc13-2527","volume":"37","author":"TS Purnell","year":"2014","unstructured":"Purnell TS, Joy S, Little E, Bridges JF, Maruthur N. Patient preferences for noninsulin diabetes medications: a systematic review. Diabetes Care. 2014;37(7):2055\u201362.","journal-title":"Diabetes Care"},{"key":"694_CR20","doi-asserted-by":"publisher","first-page":"561","DOI":"10.2147\/PPA.S187907","volume":"13","author":"VT Thieu","year":"2019","unstructured":"Thieu VT, Robinson S, Kennedy-Martin T, Boye KS, Garcia-Perez LE. Patient preferences for glucagon-like peptide 1 receptor-agonist treatment attributes. Patient Prefer Adherance. 2019;13:561\u201376.","journal-title":"Patient Prefer Adherance."},{"issue":"1","key":"694_CR21","first-page":"38","volume":"45","author":"Z Mao","year":"2024","unstructured":"Mao Z, Chuang L-H, Xie S, Wu J. A qualitative study of oral antidiabetic medication treatment preference for type 2 diabetes patients: a case study of patients in Beijing. World Clin Drug. 2024;45(1):38\u201344.","journal-title":"World Clin Drug"},{"issue":"5","key":"694_CR22","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s40271-015-0118-z","volume":"8","author":"EW de Bekker-Grob","year":"2015","unstructured":"de Bekker-Grob EW, Donkers B, Jonker MF, Stolk EA. Sample size requirements for discrete-choice experiments in healthcare: a practical guide. Patient. 2015;8(5):373\u201384.","journal-title":"Patient"},{"issue":"3","key":"694_CR23","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1002\/hec.1591","volume":"20","author":"FR Johnson","year":"2011","unstructured":"Johnson FR, Mohamed AF, Ozdemir S, Marshall DA, Phillips KA. How does cost matter in health-care discrete-choice experiments? Health Econ. 2011;20(3):323\u201330.","journal-title":"Health Econ"},{"key":"694_CR24","volume-title":"Stata statistical software: release 17","author":"StataCorp.","year":"2021","unstructured":"StataCorp. Stata statistical software: release 17. College Station: StataCorp LLC; 2021."},{"issue":"1","key":"694_CR25","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.jval.2017.07.001","volume":"21","author":"EM Janssen","year":"2018","unstructured":"Janssen EM, Hauber AB, Bridges JFP. Conducting a discrete-choice experiment study following recommendations for good research practices: an application for eliciting patient preferences for diabetes treatments. Value Health. 2018;21(1):59\u201368.","journal-title":"Value Health"},{"issue":"13","key":"694_CR26","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1517\/14656566.2015.1070827","volume":"16","author":"SR Joshi","year":"2015","unstructured":"Joshi SR, Standl E, Tong N, Shah P, Kalra S, Rathod R. Therapeutic potential of \u03b1-glucosidase inhibitors in type 2 diabetes mellitus: an evidence-based review. Expert Opin Pharmacother. 2015;16(13):1959\u201381.","journal-title":"Expert Opin Pharmacother"},{"issue":"8","key":"694_CR27","doi-asserted-by":"publisher","first-page":"641","DOI":"10.14740\/jocmr3456w","volume":"10","author":"K Suzuki","year":"2018","unstructured":"Suzuki K, Hasegawa K, Watanabe M. Efficacy and patient satisfaction of dipeptidyl peptidase-4 inhibitor after switching from once-daily DPP-4 inhibitor to once-weekly regimen. J Clin Med Res. 2018;10(8):641\u20137.","journal-title":"J Clin Med Res"},{"issue":"5","key":"694_CR28","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s40271-016-0170-3","volume":"9","author":"EM Janssen","year":"2016","unstructured":"Janssen EM, Segal JB, Bridges JF. A Framework for instrument development of a choice experiment: an application to type 2 diabetes. Patient. 2016;9(5):465\u201379.","journal-title":"Patient"},{"issue":"1","key":"694_CR29","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s40271-019-00401-x","volume":"13","author":"IL Hollin","year":"2020","unstructured":"Hollin IL, Craig BM, Coast J, Beusterien K, Vass C, DiSantostefano R, et al. Reporting formative qualitative research to support the development of quantitative preference study protocols and corresponding survey instruments: guidelines for authors and reviewers. Patient. 2020;13(1):121\u201336.","journal-title":"Patient"}],"container-title":["The Patient - Patient-Centered Outcomes Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40271-024-00694-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40271-024-00694-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40271-024-00694-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T23:19:57Z","timestamp":1724455197000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40271-024-00694-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,20]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["694"],"URL":"https:\/\/doi.org\/10.1007\/s40271-024-00694-7","relation":{},"ISSN":["1178-1653","1178-1661"],"issn-type":[{"value":"1178-1653","type":"print"},{"value":"1178-1661","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,20]]},"assertion":[{"value":"21 March 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"LC contributed to the study design, data collection, data analysis, interpretation, and manuscript drafting and review. HZ contributed to data collection, data analysis, and manuscript drafting. TH contributed to the interpretation and review. SX contributed to the study design, data analysis, interpretation, and review. All authors approved the final version of the manuscript before its submission.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"The authors declare no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was funded by the National Natural Science Foundation of China (Grant no. 72174142) and Haisco Pharmaceutical Group.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding\/support"}},{"value":"The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Role of the funder\/sponsor"}},{"value":"The study was approved by the Ethics Committee of Tianjin University (No. TJUE-2020-185), China.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics\/ethical approval"}},{"value":"The datasets generated and analyzed during the current study are not publicly available owing to the informed consent rules with respondents included in this study.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}}]}}